Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cefmenoxime. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 5/20 | 0.99 |
| ▸ | PGR | P06401 | 2/20 | 0.99 |
| ▸ | PPARG | P37231 | 2/20 | 0.76 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.76 |
| ▸ | SLC22A8 | Q8TCC7 | 2/20 | 0.76 |
| ▸ | SLC22A11 | Q9NSA0 | 2/20 | 0.76 |
| ▸ | DAO | P14920 | 1/20 | 0.76 |
| ▸ | SNCA | P37840 | 1/20 | 0.76 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.76 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.75 |
| ▸ | HTR2C | P28335 | 1/20 | 0.71 |
| ▸ | MAPT | P10636 | 5/20 | 0.69 |
| ▸ | ALB | P02768 | 1/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 7/20 | 0.68 |
| ▸ | APEX1 | P27695 | 4/20 | 0.68 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.68 |
| ▸ | POLB | P06746 | 2/20 | 0.68 |
| ▸ | RECQL | P46063 | 2/20 | 0.68 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cefmenoxime SCHEMBL192782 | 1.00 | NR1I2 (0.99) | NR1I2PGRPPARGSLC22A6SLC22A8 | |
| Cefmenoxime SCHEMBL27487467 | 1.00 | NR1I2 (0.99) | NR1I2PGRPPARGSLC22A6SLC22A8 | |
| Cefmenoxime SCHEMBL4707015 | 1.00 | NR1I2 (0.99) | NR1I2PGRPPARGSLC22A6SLC22A8 | |
| Cefmenoxime SCHEMBL3252593 | 0.99 | NR1I2 (1.00) | NR1I2PGRPPARGSLC22A6SLC22A8 | |
| Cefmenoxime SCHEMBL9659869 | 0.99 | NR1I2 (1.00) | NR1I2PGRPPARGSLC22A6SLC22A8 | |
| Cefmenoxime SCHEMBL8768620 | 0.99 | NR1I2 (1.00) | NR1I2PGRPPARGSLC22A6SLC22A8 | |
| Cefmenoxime SCHEMBL10633730 | 0.99 | NR1I2 (1.00) | NR1I2PGRPPARGSLC22A6SLC22A8 | |
| Cefmenoxime SCHEMBL1813696 | 0.99 | NR1I2 (1.00) | NR1I2PGRPPARGSLC22A6SLC22A8 | |
| Cefmenoxime SCHEMBL152861 | 0.99 | NR1I2 (1.00) | NR1I2PGRPPARGSLC22A6SLC22A8 | |
| Cefmenoxime SCHEMBL10492342 | 0.99 | NR1I2 (1.00) | NR1I2PGRPPARGSLC22A6SLC22A8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1366 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119970732-A | Antibacterial composition with synergistic effect and application thereof | 南京工业大学 | 2025-05-13 | — | — | CN | claimed |
| CN-119215055-B | Application of cefmenoxime hydrochloride in preparation of medicine for treating diseases caused by mycobacterium tuberculosis infection and/or nontuberculous mycobacterial infection | 深圳国家感染性疾病临床医学研究中心 | 2025-02-18 | — | — | CN | claimed |
| CN-119215055-A | Application of cefmenoxime hydrochloride in preparation of medicine for treating diseases caused by mycobacterium tuberculosis infection and/or nontuberculous mycobacterial infection | 深圳国家感染性疾病临床医学研究中心 | 2024-12-31 | — | — | CN | claimed |
| CN-117520090-A | Call chain selection method and device | 中国工商银行股份有限公司 | 2024-02-06 | — | — | CN | claimed |
| CN-117384259-A | Cell penetrating peptides based on influenza virus M2 proteins | 中国医学科学院基础医学研究所 | 2024-01-12 | — | — | CN | claimed |
| CN-117275179-A | Calling method of bedside calling panel, bedside calling panel and storage medium | 深圳市启鹏天辰科技有限公司 | 2023-12-22 | — | — | CN | claimed |
| CN-112912386-B | Cell penetrating peptides based on influenza virus M2 proteins | 中国医学科学院基础医学研究所 | 2023-10-20 | — | — | CN | claimed |
| CN-116350632-A | Application of cephalosporin antibiotics in preparation of targeted anticancer drugs or auxiliary anticancer health care products | 昆明医科大学 | 2023-06-30 | — | — | CN | claimed |
| US-11601552-B2 | Hierarchical interface for adaptive closed loop communication system | GRIDSPACE INC. (US) | 2023-03-07 | — | — | US | claimed |
| CN-114666305-A | IP call method, system, device, electronic equipment and storage medium | 迈普通信技术股份有限公司 | 2022-06-24 | — | — | CN | claimed |
| US-20070093462-A1 | Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients | BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA | 2007-04-26 | — | — | US | claimed |
| WO-2007044693-A2 | MULTI-FUNCTIONAL IONIC LIQUID COMPOSITIONS | THE UNIVERSITY OF ALABAMA (US) | 2007-04-19 | — | — | WO | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| EP-1578434-A2 | METHODS AND COMPOSITIONS RELATING TO ISOLEUCINE BOROPROLINE COMPOUNDS | Point Therapeutics, Inc. (US) | 2005-09-28 | — | — | EP | claimed |
| US-20040131628-A1 | Nucleic acids for the treatment of disorders associated with microorganisms | BRATZLER ROBERT L (US) | 2004-07-08 | — | — | US | claimed |
| WO-2004004658-A2 | METHODS AND COMPOSITIONS RELATING TO ISOLEUCINE BOROPROLINE COMPOUNDS | POINT THERAPEUTICS, INC. (US) | 2004-01-15 | — | — | WO | claimed |
| US-6642377-B1 | Subjecting oxalate to salt exchange with alkali earth metal salt | EISAI CO., LTD. (JP) | 2003-11-04 | — | — | US | claimed |
| EP-1201665-A1 | PROCESS FOR THE PREPARATION OF BASIC ANTIBIOTIC-INORGANIC ACID ADDITION SALTS AND INTERMEDIATE OXALATES | Eisai Co., Ltd. (JP) | 2002-05-02 | — | — | EP | claimed |
| US-6245735-B1 | CONJUGATE OF ANTIBIOTIC AND POLYPEPTIDE OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR OR LIPOPOLYSACCHARIDE BINDING FRAGMENT | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2001-06-12 | — | — | US | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093462-A1 | Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients | SLC5A6, PNLIP, IPMK | NR1I2 3832/4885PGR 2346/4885PPARG 226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.